SIK1 and pulmonary arterial hypertension: Pharmacological SIK inhibition or AAV9-mediated Sik1 knockdown in smooth muscles aggravates RV hypertrophy and pulmonary arterial remodeling in a hypoxia-induced PAH mouse model (Pu et al., 2022).